Hepatitis C, Direct-Acting Antivirals

← Back to Class List

PDL Status Values

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.

To request a Prior Authorization, please use this form.

Generic Name Brand Name Form PDL
Status
Current Drug Use Criteria New Drug Evaluation
glecaprevir/pibrentasvir MAVYRET TABLET Y Quantity Limit  
sofosbuvir/velpatasvir SOFOSBUVIR-VELPATASVIR TABLET Y Quantity Limit  
elbasvir/grazoprevir ZEPATIER TABLET N Quantity Limit  
glecaprevir/pibrentasvir MAVYRET PELET PACK N Quantity Limit  
ledipasvir/sofosbuvir HARVONI PELET PACK N Quantity Limit  
ledipasvir/sofosbuvir HARVONI TABLET N Quantity Limit  
ledipasvir/sofosbuvir LEDIPASVIR-SOFOSBUVIR TABLET N Quantity Limit  
sofosbuvir SOVALDI PELET PACK N Quantity Limit  
sofosbuvir SOVALDI TABLET N Quantity Limit Jan 30, 2014
sofosbuvir/velpatas/voxilaprev VOSEVI TABLET N Quantity Limit  
sofosbuvir/velpatasvir EPCLUSA PELET PACK N Quantity Limit  
sofosbuvir/velpatasvir EPCLUSA TABLET N Quantity Limit